

## INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

10/528688

Sheet 1 of 1

ATTY. REF. NO.  
3012-000 PCT/PTC  
APPLICATION NO.  
Not Yet Known  
APPLICANT  
FOSTER ET AL.  
FILING DATE  
Herewith

21 MAR 2005

Group

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						
AJ						
AK						
AL						

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES NO
AM	197 39 693	3/11/99	DE			<input type="checkbox"/> <input type="checkbox"/>
AN	1 002 792	5/24/00	EP			<input type="checkbox"/> <input type="checkbox"/>
AO	02/072019	9/19/02	WO			<input type="checkbox"/> <input type="checkbox"/>
AP	02/18395	3/7/02	WO			<input type="checkbox"/> <input type="checkbox"/>
AQ						<input type="checkbox"/> <input type="checkbox"/>

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

AR	Brinkman et al., "The Immune Modulator FTY720 Targets Sphingosine 1-Phosphate Receptors", J. Biol. Chem., Vol. 277, No. 24, pp. 21453-21457 (2002).
AS	Brinkman et al., "FTY720: Targeting G-Protein-Coupled Receptors for Sphingosine 1-Phosphate in Transplantation and Autoimmunity", Current Opinion in Immunology, Vol. 14, No. 5, pp. 569-575 (2002).
AT	Hoshino et al., "FTY720, a Novel Immunosuppressant, Shows a Synergistic Effect in Combination with FK 506 in Rat Allograft Models", Transplantation Proceedings, Vol. 31, No. 1-2, pp. 1224-1226 (1999).
AU	Moser, "Clinical and Therapeutic Aspects of Adrenoleukodystrophy and Adrenomyeloneuropathy", J. Neuropathology and Experimental Neurology, Vol. 54, No. 5, pp. 740-745 (1995).

EXAMINER

/Sahar Javanmard/

DATE CONSIDERED

06/19/2008

\*EXAMINER:

Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.